United Therapeutics Corp
UTHR485.360USD
+6.430+1.34%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
20.82BMarket Cap
17.05P/E TTM
More Details of United Therapeutics Corp Company
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
United Therapeutics Corp Info
Ticker SymbolUTHR
Company nameUnited Therapeutics Corp
IPO dateJun 17, 1999
CEORothblatt (Martine A)
Number of employees1305
Security typeOrdinary Share
Fiscal year-endJun 17
Address1000 Spring St
CitySILVER SPRING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20910
Phone13016089292
Websitehttps://www.unither.com/
Ticker SymbolUTHR
IPO dateJun 17, 1999
CEORothblatt (Martine A)
Company Executives of United Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+1190.00%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.29K
-187.00%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
+3200.00%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+71.00%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
--
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
320.00
-100.00%
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
Prof. Raymond A. Dwek, CBE
Prof. Raymond A. Dwek, CBE
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+1190.00%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.29K
-187.00%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
+3200.00%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+71.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Tyvaso DPI
336.20M
42.05%
Nebulized Tyvaso
141.80M
17.74%
Orenitram
131.10M
16.40%
Remodulin
125.90M
15.75%
Unituxin
47.90M
5.99%
Other
16.60M
2.08%
By RegionUSD
Name
Revenue
Proportion
United States
774.80M
96.91%
Rest of World
24.70M
3.09%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Tyvaso DPI
336.20M
42.05%
Nebulized Tyvaso
141.80M
17.74%
Orenitram
131.10M
16.40%
Remodulin
125.90M
15.75%
Unituxin
47.90M
5.99%
Other
16.60M
2.08%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
9.90%
The Vanguard Group, Inc.
9.65%
Renaissance Technologies LLC
5.05%
Avoro Capital Advisors LLC
4.70%
State Street Investment Management (US)
4.47%
Other
66.24%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
9.90%
The Vanguard Group, Inc.
9.65%
Renaissance Technologies LLC
5.05%
Avoro Capital Advisors LLC
4.70%
State Street Investment Management (US)
4.47%
Other
66.24%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.30%
Investment Advisor/Hedge Fund
33.68%
Hedge Fund
13.61%
Research Firm
2.96%
Pension Fund
2.63%
Individual Investor
1.84%
Bank and Trust
1.42%
Sovereign Wealth Fund
1.29%
Venture Capital
0.46%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1439
42.90M
99.63%
-3.07M
2025Q3
1348
44.10M
102.42%
-3.87M
2025Q2
1338
46.42M
102.62%
-2.51M
2025Q1
1369
46.67M
103.49%
-1.81M
2024Q4
1344
46.07M
102.60%
-3.00M
2024Q3
1278
45.38M
101.97%
-7.63M
2024Q2
1219
48.02M
108.26%
-2.92M
2024Q1
1151
47.12M
106.59%
-2.41M
2023Q4
1127
46.52M
99.01%
-2.26M
2023Q3
1094
46.35M
98.80%
-3.96M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.26M
9.9%
-76.88K
-1.77%
Sep 30, 2025
The Vanguard Group, Inc.
4.40M
10.22%
-31.08K
-0.70%
Sep 30, 2025
Renaissance Technologies LLC
2.17M
5.05%
+54.30K
+2.56%
Sep 30, 2025
Avoro Capital Advisors LLC
2.02M
4.7%
-347.78K
-14.67%
Sep 30, 2025
State Street Investment Management (US)
1.92M
4.47%
-244.90K
-11.30%
Sep 30, 2025
Wellington Management Company, LLP
1.40M
3.25%
-44.16K
-3.06%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.25M
2.9%
+49.30K
+4.11%
Sep 30, 2025
AQR Capital Management, LLC
986.48K
2.29%
-286.68K
-22.52%
Sep 30, 2025
Darwin Global Management Ltd
748.55K
1.74%
+748.55K
--
Sep 30, 2025
Rothblatt (Martine A)
666.42K
1.55%
--
--
Dec 19, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Health Care ETF
5.9%
Formidable Fortress ETF
4.22%
Franklin Genomic Advancements ETF
4.09%
First Trust NASDAQ Pharmaceuticals ETF
3.87%
Invesco Pharmaceuticals ETF
3.85%
Invesco Biotechnology & Genome ETF
3.82%
Invesco S&P MidCap Quality ETF
3.74%
Inspire Growth ETF
3.7%
VanEck Biotech ETF
3.58%
First Trust NYSE Arca Biotechnology Index Fund
3.4%
View more
Simplify Health Care ETF
Proportion5.9%
Formidable Fortress ETF
Proportion4.22%
Franklin Genomic Advancements ETF
Proportion4.09%
First Trust NASDAQ Pharmaceuticals ETF
Proportion3.87%
Invesco Pharmaceuticals ETF
Proportion3.85%
Invesco Biotechnology & Genome ETF
Proportion3.82%
Invesco S&P MidCap Quality ETF
Proportion3.74%
Inspire Growth ETF
Proportion3.7%
VanEck Biotech ETF
Proportion3.58%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.4%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
